A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Oedema Secondary to Central Retinal Vein Occlusion

Trial Profile

A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Oedema Secondary to Central Retinal Vein Occlusion

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Central retinal vein occlusion; Retinal oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms CRUISE
  • Sponsors Genentech
  • Most Recent Events

    • 15 Aug 2014 New trial record
    • 06 May 2010
    • 03 Feb 2009
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top